Use of H19 Gene Regulatory Sequences in DNA-Based  Therapy for Pancreatic Cancer

<table>Effect of DTA-H19 treatment in Tumor Growth Progression and ex vivo tumor size on the orthotopic pancreatic carcinoma in the hamster. (a) Average of tumor growth progression of the DTA-H19 (<svg height="7.1374998" id="M37" style="vertical-align:-0.10033pt" version="1.1" viewbox="0 0 7.8874998 7.1374998" width="7.8874998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,7.1375)">
<g transform="translate(72,-66.29)">
<text transform="matrix(1,0,0,-1,-71.95,66.44)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
</text>
</g>
</g>
</svg> = 9) and Luc-H19 (<svg height="7.1374998" id="M38" style="vertical-align:-0.10033pt" version="1.1" viewbox="0 0 7.8874998 7.1374998" width="7.8874998" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,7.1375)">
<g transform="translate(72,-66.29)">
<text transform="matrix(1,0,0,-1,-71.95,66.44)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑛</tspan>
</text>
</g>
</g>
</svg> = 7) treated groups calculated as the ratio of tumor size at the end of the experiment (day 11 after cells implantation) compared to the size before treatment (day 7 after cells implantation). (b) Average of <i>ex vivo</i> tumor volume of the treated (DTA-H19) and control group (Luc-H19) measured after sacrifice (day 11). (c) The left picture corresponds to a tumor treated with DTA-H19 plasmid, and the right picture corresponds to a tumor from the control group.</table>

Journal of Oncology

fig6

Figure 6

Figure 6: Use of H19 Gene Regulatory Sequences in DNA-Based  Therapy for Pancreatic Cancer 